



## Covid-19: Medicines Criticality Groups

Department of Health, Miesian Plaza,

Wednesday, 18<sup>th</sup> March 2020

No	Action Detail	Owner	By When	Update	Status
1	Look at medicines used in Irish hospitals that may potentially be used to treat Covid 19, to treat secondary infections and as supportive treatments	AMRIC & AHDMP (HSE)	10/03/20	V.2 of the protocol to be informed by NPHEE Ethics subgroup	
2	MAHs to be contacted re availability of medicines referred to above	AHDMP		AHDMP has contacted all MAH holders. Midazolam stock flagged by HPRA	
3	Discussion with HBS re potential central procurement of medicines to treat Covid 19, to treat secondary infections and as supportive treatments. Consideration as to how private hospitals are to be included.	Acute Strategy & Planning & ADHMP (HSE)	10/03/20		Closed
4	HSE Modelling data to be shared with group when available	Department of Health	10/03/20	Not yet issued by NPHEE	
5	PCRS to contact relevant MAH re available supply of hydroxychloroquine	PCRS	13/03/20		Closed
6	PCRS to issue communication re use of hydroxychloroquine	PCRS	13/03/20	PCRS in process of issuing comms	Closed (if distinct from Action 14)
7	Contact MAH re availability Oseltamivir	AHDMP	13/03/20	PCRS to monitor usage in the community	Closed
8	HPRA to develop template to capture the order of review of medicines, details of medicines to be considered and	HPRA	13/03/20		Closed



	companies contacted and a summary of those contacts				
9	HPRA to provide update on status of questionnaire to MAHs	HPRA	13/03/20	HPRA to circulate once received	
10	DoH to issue communication from group chair to relevant stakeholders	Department of Health	13/03/20	Completed	Closed
11	Contact supplier re TPN	AHDMP	13/03/20	stock status green. Still awaiting supplier response	
12	AHDMP to send guidance for hospitals document to Prof. Bergin	AHDMP	13/03/20		Closed
13	Group to review impact of comms as regards the perceived pull on supply chains	DoH / HPRA	Ongoing		
14	PCRS to update Group on mechanism to ensure sufficient stock of hydroxychloroquine to treat patients already undergoing treatment with hydroxychloroquine (not for antiviral purposes) by limiting de novo patients on for antiviral purposes	PCRS & AHDMP	18/03/20	Letter drafted, signed and to be circulated by	
15	Issue for discussion: NCCP query re. tocilizumab, hydroxychloroquine and blood products	For discussion during call	18/03/20	NCCP to tie in with Blood Transfusion Service and Acute Strategy & Planning	Closed
16	Ongoing contact with IBTS and alert Group of issues with stock of sanitizer, masks, aprons	Acute Strategy & Planning	Ongoing		